CSIMarket
 


Immunic Inc   (IMUX)
Other Ticker:  
 
 

IMUX's Net Income Growth by Quarter and Year

Immunic Inc 's Net Income results by quarter and year




IMUX Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -21.19 -11.16 -2.51
III Quarter September -21.22 -19.29 -12.91 -8.22
II Quarter June -21.90 -17.93 -11.46 -14.71
I Quarter March -20.81 -34.53 -8.49 -9.49
FY   -63.93 -92.94 -44.02 -34.93



IMUX Net Income third quarter 2022 Y/Y Growth Comment
Immunic Inc in the third quarter 2022 recorded net loss of $ -21.22 millions.

According to the results reported in the third quarter 2022, Immunic Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Immunic Inc ' s Net Income no change of % ranks overall at the positon no. in the third quarter 2022.




IMUX Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Immunic Inc 's third quarter 2022 Net Income $ -21.22 millions IMUX's Income Statement
Immunic Inc 's third quarter 2021 Net Income $ -19.29 millions Quarterly IMUX's Income Statement
New: More IMUX's historic Net Income Growth >>


IMUX Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Immunic Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMUX's III. Quarter Q/Q Net Income Comment
Even if Immunic Inc in the III. Quarter 2022 revealed net loss of $ -21.22 millions, it should be said, that current results are recovery in contrast to the -21.90 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Immunic Inc achieved highest sequential Net Income growth. While Immunic Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMUX's III. Quarter Q/Q Net Income Comment
Even if Immunic Inc in the III. Quarter 2022 admitted net loss of $ -21.22 millions, some analyst said, that current results point to recovery relative to the -21.90 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Immunic Inc achieved highest sequential Net Income growth. While Immunic Inc 's Net Income growth quarter on quarter, overall rank is .


Immunic Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Net Income 12 Months Ending $ -85.12 $ -83.19 $ -79.22 $ -92.95 $ -82.92
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Immunic Inc ' has realized cumulative trailing twelve months net loss of $ -85 millions in the Sep 30 2022 period.
The situation is getting worse as the cumulative net loss is becoming larger from $ -83.19 millions in TTM ending quarter Jun 30 2022 and $ -21.9 millions for the twelve months ending in the quarter a year ago Riley T. Mitchell wrote.

Immunic Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Immunic Inc ' has realized cumulative trailing twelve months net loss of $ -85 millions in the Sep 30 2022 period.
The business is getting worse as the cumulative net loss is inflating from $ -83.19 millions in TTM ending quarter Jun 30 2022 and $ -21.9 millions from the TTM period ending Sep 30 2021 Riley T. Mitchell wrote.

Immunic Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
IMUX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for IMUX's Competitors
Net Income Growth for Immunic Inc 's Suppliers
Net Income Growth for IMUX's Customers

You may also want to know
IMUX's Annual Growth Rates IMUX's Profitability Ratios IMUX's Asset Turnover Ratio IMUX's Dividend Growth
IMUX's Roe IMUX's Valuation Ratios IMUX's Financial Strength Ratios IMUX's Dividend Payout Ratio
IMUX's Roa IMUX's Inventory Turnover Ratio IMUX's Growth Rates IMUX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2022
Ensign Group Inc16.34%$ 16.337 millions
Integra Lifesciences Holdings Corp15.47%$ 15.466 millions
Amgen Inc 13.75%$ 13.747 millions
Viatris Inc 13.74%$ 13.740 millions
Corcept Therapeutics Inc13.39%$ 13.386 millions
Prestige Consumer Healthcare Inc 12.06%$ 12.063 millions
Assertio Holdings inc 11.69%$ 11.694 millions
Syneos Health Inc 11.25%$ 11.255 millions
Option Care Health Inc 9.43%$ 9.435 millions
Vertex Pharmaceuticals Inc9.22%$ 9.223 millions
Becton Dickinson And Company8.75%$ 8.745 millions
Iqvia Holdings Inc 8.43%$ 8.429 millions
Mettler Toledo International Inc8.30%$ 8.301 millions
Acadia Healthcare Company Inc 7.58%$ 7.579 millions
Atrion Corporation6.79%$ 6.790 millions
Avantor Inc 6.51%$ 6.505 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ETON's Profile

Stock Price

ETON's Financials

Business Description

Fundamentals

Charts & Quotes

ETON's News

Suppliers

ETON's Competitors

Customers & Markets

Economic Indicators

ETON's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071